Hyperfractionated Cyclophosphamide and Dexamethasone Alone or in Combination with Daratumumab and/or Carfilzomib for the Treatment of Relapsed or Refractory Multiple Myeloma: A Single-Center Retrospective Analysis

Shank, Brandon R.; Primeaux, Brian; Yeung, EK; Horowitz, SB; Lee, IY; Roccograndi, L; Liu, Feng; Kaufman, GP; Hc, Lee; Manasanch, Elisabet E.; Patel, KK; Orlowski, RZ; Weber, DM; Becnel, MR; Thomas, Sheeba K.

doi:10.1016/j.clml.2022.12.004

Cited by 5 publications

(1 citation statement)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Studies have reported that high-dose cyclophosphamide or hyperfractionated cyclophosphamide is efficacious particularly in patients needing immediate disease control who have received multiple prior treatments. 90,91 Therefore the NCCN Guidelines Panel has included high dose or fractionated cyclophosphamide as an option for relapsed/refractory MM.…”

Section: High-dose or Fractionated Cyclophosphamidementioning

confidence: 99%

Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Kumar,

Callander,

Adekola

et al. 2023

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

The treatment of relapsed/refractory multiple myeloma (MM) has evolved to include several new options. These include new combinations with second generation proteasome inhibitors (PI); second generation immunomodulators, monoclonal antibodies, CAR T cells, bispecific antibodies, selinexor, venetoclax, and many others. Most patients with MM undergo several cycles of remissions and relapse, and therefore need multiple lines of combination therapies. Selecting treatment options for relapsed/refractory MM requires consideration of resistance status to specific classes, and patient-specific factors such as age and other comorbidities should be considered. The NCCN Guidelines for MM provide a framework on which to base decisions regarding workup, treatment, and follow-up of newly diagnosed and previously treated MM. This manuscript outlines the recommendations from NCCN Guidelines for MM specific to relapsed/refractory disease.

show abstract

Section: High-dose or Fractionated Cyclophosphamidementioning

confidence: 99%

Multiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology

Kumar,

Callander,

Adekola

et al. 2023

Journal of the National Comprehensive Cancer Network

View full text Add to dashboard Cite

show abstract

Rapid high‐dose cyclophosphamide as bridging treatment for advanced therapies in multiple myeloma

Marable,

Kelly,

Cooperrider

et al. 2024

eJHaem

View full text Add to dashboard Cite

Patients with relapsed/refractory multiple myeloma proceeding with chimeric antigen receptor (CAR) T‐cell therapy or bispecific antibodies (BsAb) may need bridging therapy to realize their benefits. We evaluated the efficacy and safety of rapid, peripheral, high‐dose cyclophosphamide (TurboCy) in 15 patients intending to proceed with CAR T‐cell therapy, BsAbs, or long‐term regimens. The overall response rate was 80% and the clinical benefit rate was 100% in a heavily pretreated high‐risk cohort. Cytopenias were common but no deaths occurred during bridging. All patients proceeded to their next line of intended therapy. TurboCy is an effective and safe bridging strategy.

show abstract